10:24 AM EDT, 09/04/2024 (MT Newswires) -- Tempus AI ( TEM ) said Wednesday it has entered a multiyear collaboration with BioNTech (BNTX) to use its multimodal datasets to support the biotechnology company's oncology pipeline.

Under the collaboration, Tempus will provide analytical support and BioNTech will use its database to produce new insights into the biological mechanisms supporting the discovery of new therapies for cancer patients.

Tempus shares were up 1.1% in recent trading, while BioNTech was unchanged.

Price: 53.15, Change: +1.06, Percent Change: +2.03